Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 13-year-old boy with acute myelogenous leukemia resistant to conventional chemotherapy received a bone marrow transplant from his HL-A-identical, mixed lymphocyte culture-reactive sister. The recipient was prepared for transplantation with cyclophosphamide and total body irradiation. Despite cytogenetic evidence of engraftment, graft-versus-host disease was not observed. The patient died 38 days post-transplantation of
Gram-negative bacteremia
sepsis and recurrent
leukemia
of recipient origin.
...
PMID:Bone marrow transplantation between mixed lymphocyte culture-reactive individuals. 12 39
We did a retrospective study of all acute lymphoblastic
leukaemia
(ALL) patients on United Kingdom ALL protocol who were admitted for febrile neutropenia. The aim of the study was to document the types of infections and aetiological agents associated with febrile neutropenia and to document the factors affecting mortality. Over the 8 1/2-year period from 1986 to June 1995, there were 77 episodes in 32 children with a mean of 2.4 episodes. Morbidity due to infection was 61%; unknown causes of fever contributed 39%. Of the microbiologically documented infections, majority were
Gram-negative bacteraemia
. There were 7 deaths (22%) during the study period, 3 (9%) of which were due to overwhelming sepsis, with 4 contributed by the relapse status of the
leukaemia
. Mortality was increased by prolonged neutropenia, relapse of the
leukaemia
and invasive fungal infection.
...
PMID:Infections in acute lymphoblastic leukaemia. 979 52
Polyclonal bacteremic episodes are caused by more than one genotype of the same species. We conducted a study to estimate the frequency and to describe the epidemiology of polyclonal
Gram-negative bacteremia
in our patient population. We reviewed the patients' medical records. We also did pulsed field gel electrophoresis on 66 Gram-negative isolates obtained from the 28 patients (29 episodes) who had more than one morphologically different isolate of the same Gram-negative species in a blood culture obtained between January 1, 1989 and December 31, 1993. Nine of 29 (31%) bacteremic episodes evaluated were polyclonal. The source of bacteremia was not significantly different among patients with polyclonal and monoclonal bacteremic episodes. Patients with polyclonal bacteremic episodes were younger and were more likely to have rapidly fatal diseases than were those with monoclonal bacteremic episodes; however, neither of these differences reached statistical significance. Patients with polyclonal bacteremic episodes were significantly more likely to have
leukemia
than were those with monoclonal bacteremic episodes (odds ratio = 18.67; 95% confidence interval, 1.92 to 255.80). Three of nine patients who had polyclonal bacteremia died compared with 2 of 19 patients who had monoclonal bacteremia (odds ratio = 4.25; 95% confidence interval, 0.41 to 50.80). Polyclonal
Gram-negative bacteremia
is more common than previously thought. Despite their younger age, patients with polyclonal bacteremic episodes were more likely to die than those with monoclonal bacteremic episodes. Thus, polyclonal bacteremia may be either an indicator or a risk factor for poor prognosis.
...
PMID:Epidemiology of polyclonal gram-negative bacteremia. 979 51
This study examined the association between type of haematological malignancy, risk of bacteraemia and risk of mortality, with emphasis on the impact of bacteraemia type on mortality. A population-based cohort design was used, and all patients aged > or = 15 years with an incident haematological malignancy who were living in North Jutland County, Denmark, during 1992-2002 were included in the study. Among 1666 patients with an incident haematological malignancy, 358 (21%) suffered an episode of bacteraemia during a median follow-up period of 1.1 years (quartile 0.2-3.4) from the date of cancer diagnosis (overall incidence rate of 96/1000 person-years). In comparison to Hodgkin's disease, adjusted incidence rate ratios (IRRs) were 23.3 (95% CI, 10.0-54.5) for acute myeloid leukaemia, 3.8 (95% CI, 1.5-9.3) for multiple myeloma, and 2.2 (95% CI, 0.9-5.1) for non-Hodgkin's lymphoma or chronic lymphatic
leukaemia
. Overall cumulative 30-day mortality was 32% (95% CI, 27-37), and 90-day mortality was 50% (95% CI, 44-55). In comparison with acute myeloid leukaemia, adjusted mortality rate ratios (MRRs) were close to 1.0 for other haematological malignancies. In comparison to bacteraemia caused by Gram-positive bacteria, adjusted MRRs were 1.0 (95% CI, 0.6-1.5) for
Gram-negative bacteraemia
, and 1.9 (95% CI, 1.1-3.3) for polymicrobial bacteraemia or fungaemia. Thus, the risk of bacteraemia varied greatly according to the type of malignancy, while mortality rates were similar for these diseases, although dependent on the type of bacteraemia. Polymicrobial bacteraemia or fungaemia was associated with higher mortality.
...
PMID:Risk of bacteraemia and mortality in patients with haematological malignancies. 1645 7